Ifosfamide

Generic Name
Ifosfamide
Brand Names
Ifex
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
3778-73-2
Unique Ingredient Identifier
UM20QQM95Y
Background

Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication

Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...

Associated Conditions
Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
Associated Therapies
-
Clinical Trials
Related News

A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

First Posted Date
2019-08-05
Last Posted Date
2022-09-14
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
240
Registration Number
NCT04044222
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

First Posted Date
2019-08-05
Last Posted Date
2020-05-19
Lead Sponsor
Peking University People's Hospital
Registration Number
NCT04044378
Locations
🇨🇳

Lu Xie, Beijing, Beijing, China

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

First Posted Date
2019-08-02
Last Posted Date
2024-07-10
Lead Sponsor
University Hospital Muenster
Target Recruit Count
683
Registration Number
NCT04043494
Locations
🇳🇱

Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands

🇫🇷

Unité d'hématologie pédiatrique CHRU de Lille - Hôpital Jeanne de Flandre, Lille, France

🇧🇪

UZ Antwerpen Kinderhemato-oncologie, Edegem, Belgium

and more 219 locations

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

First Posted Date
2018-11-09
Last Posted Date
2022-07-22
Lead Sponsor
Swedish Medical Center
Target Recruit Count
47
Registration Number
NCT03736616
Locations
🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

First Posted Date
2018-10-25
Last Posted Date
2023-10-26
Lead Sponsor
New York Medical College
Target Recruit Count
40
Registration Number
NCT03719105
Locations
🇺🇸

Children's Hospital Orange County, Orange, California, United States

🇺🇸

Helen De Vos, Grand Rapids, Michigan, United States

🇺🇸

University of Alabama, Birmingham, Alabama, United States

and more 3 locations

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

First Posted Date
2018-08-22
Last Posted Date
2023-11-29
Lead Sponsor
Martin Schrappe
Target Recruit Count
5000
Registration Number
NCT03643276
Locations
🇮🇹

AOUC Policlinico Bari, Bari, Italy

🇮🇹

A.O. Papa Giovanni XXIII, Bergamo, Italy

🇮🇹

S.O. Annunziata - A. O. Cosenza, Cosenza, Italy

and more 111 locations

Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

First Posted Date
2018-08-14
Last Posted Date
2018-09-19
Lead Sponsor
Samsung Medical Center
Target Recruit Count
46
Registration Number
NCT03628131
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

First Posted Date
2018-02-22
Last Posted Date
2024-03-29
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
16
Registration Number
NCT03440567
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase 2
Recruiting
Conditions
Clonal Cytopenia of Undetermined Significance
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Hodgkin Lymphoma
Recurrent Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Lymphoma
Chronic Myelomonocytic Leukemia
Interventions
Dietary Supplement: Ascorbic Acid
Drug: Carboplatin
Drug: Decitabine
Drug: Cisplatin
Drug: Cytarabine
Drug: Dexamethasone
Drug: Etoposide
Drug: Gemcitabine Hydrochloride
Procedure: Central Venous Cannula Insertion
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Procedure: Portacath Placement
Other: Questionnaire Administration
Biological: Rituximab
Drug: Oxaliplatin
Procedure: Biospecimen Collection
Procedure: Core Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography
Procedure: Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Computed Tomography
First Posted Date
2018-02-01
Last Posted Date
2024-08-05
Lead Sponsor
Mayo Clinic
Target Recruit Count
80
Registration Number
NCT03418038
Locations
🇺🇸

Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States

🇺🇸

Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States

🇺🇸

Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States

and more 1 locations

Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL

First Posted Date
2017-12-08
Last Posted Date
2020-03-11
Lead Sponsor
Ruijin Hospital
Target Recruit Count
39
Registration Number
NCT03367143
Locations
🇨🇳

Shanghai Ruijin Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy